Literature DB >> 23485381

Acceptance of treatment for latent tuberculosis infection: prospective cohort study in the United States and Canada.

P W Colson1, Y Hirsch-Moverman, J Bethel, P Vempaty, K Salcedo, K Wall, W Miranda, S Collins, C R Horsburgh.   

Abstract

SETTING: An estimated 300 000 individuals are treated for latent tuberculosis infection (LTBI) in the United States and Canada annually. Little is known about the proportion or characteristics of those who decline treatment.
OBJECTIVE: To define the proportion of individuals in various groups who accept LTBI treatment and to identify factors associated with non-acceptance of treatment.
DESIGN: Persons offered LTBI treatment at 30 clinics in 12 Tuberculosis Epidemiologic Studies Consortium sites were prospectively enrolled. Multivariate regression models were constructed based on manual stepwise assessment of potential predictors.
RESULTS: Of 1692 participants enrolled from March 2007 to September 2008, 1515 (89.5%) accepted treatment and 177 (10.5%) declined. Predictors of acceptance included believing one could personally spread TB germs, having greater TB knowledge, finding clinic schedules convenient and having low acculturation. Predictors of non-acceptance included being a health care worker, being previously recommended for treatment and believing that taking medicines would be problematic.
CONCLUSION: This is the first prospective multisite study to examine predictors of LTBI treatment acceptance in general clinic populations. Greater efforts should be made to increase acceptance among health care workers, those previously recommended for treatment and those who expect problems with LTBI medicines. Ensuring convenient clinic schedules and TB education to increase knowledge could be important for ensuring acceptance.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23485381     DOI: 10.5588/ijtld.12.0697

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  14 in total

1.  Latent tuberculous infection in the United States and Canada: who completes treatment and why?

Authors:  Y Hirsch-Moverman; R Shrestha-Kuwahara; J Bethel; H M Blumberg; T K Venkatappa; C R Horsburgh; P W Colson
Journal:  Int J Tuberc Lung Dis       Date:  2015-01       Impact factor: 2.373

Review 2.  Old and new approaches to diagnosing and treating latent tuberculosis in children in low-incidence countries.

Authors:  Andrea T Cruz; Jeffrey R Starke; Mark N Lobato
Journal:  Curr Opin Pediatr       Date:  2014-02       Impact factor: 2.856

3.  Female sex and discontinuation of isoniazid due to adverse effects during the treatment of latent tuberculosis.

Authors:  April C Pettit; James Bethel; Yael Hirsch-Moverman; Paul W Colson; Timothy R Sterling
Journal:  J Infect       Date:  2013-07-08       Impact factor: 6.072

4.  Seven-year retrospective study understanding the latent TB infection treatment cascade of care among adults in a low incidence country.

Authors:  K Sullivan; C Pease; A Zwerling; R Mallick; D Van Dyk; S Mulpuru; C Allen; H Alsdurf; G G Alvarez
Journal:  BMC Public Health       Date:  2021-05-21       Impact factor: 3.295

5.  Cost-effectiveness of Testing and Treatment for Latent Tuberculosis Infection in Residents Born Outside the United States With and Without Medical Comorbidities in a Simulation Model.

Authors:  Abriana Tasillo; Joshua A Salomon; Thomas A Trikalinos; C Robert Horsburgh; Suzanne M Marks; Benjamin P Linas
Journal:  JAMA Intern Med       Date:  2017-12-01       Impact factor: 44.409

6.  Self-reported Engagement in Care among U.S. Residents with Latent Tuberculosis Infection: 2011-2012.

Authors:  James D Mancuso; Roque Miramontes; Carla A Winston; C Robert Horsburgh; Andrew N Hill
Journal:  Ann Am Thorac Soc       Date:  2021-10

Review 7.  Towards tuberculosis elimination: an action framework for low-incidence countries.

Authors:  Knut Lönnroth; Giovanni Battista Migliori; Ibrahim Abubakar; Lia D'Ambrosio; Gerard de Vries; Roland Diel; Paul Douglas; Dennis Falzon; Marc-Andre Gaudreau; Delia Goletti; Edilberto R González Ochoa; Philip LoBue; Alberto Matteelli; Howard Njoo; Ivan Solovic; Alistair Story; Tamara Tayeb; Marieke J van der Werf; Diana Weil; Jean-Pierre Zellweger; Mohamed Abdel Aziz; Mohamed R M Al Lawati; Stefano Aliberti; Wouter Arrazola de Oñate; Draurio Barreira; Vineet Bhatia; Francesco Blasi; Amy Bloom; Judith Bruchfeld; Francesco Castelli; Rosella Centis; Daniel Chemtob; Daniela M Cirillo; Alberto Colorado; Andrei Dadu; Ulf R Dahle; Laura De Paoli; Hannah M Dias; Raquel Duarte; Lanfranco Fattorini; Mina Gaga; Haileyesus Getahun; Philippe Glaziou; Lasha Goguadze; Mirtha Del Granado; Walter Haas; Asko Järvinen; Geun-Yong Kwon; Davide Mosca; Payam Nahid; Nobuyuki Nishikiori; Isabel Noguer; Joan O'Donnell; Analita Pace-Asciak; Maria G Pompa; Gilda G Popescu; Carlos Robalo Cordeiro; Karin Rønning; Morten Ruhwald; Jean-Paul Sculier; Aleksandar Simunović; Alison Smith-Palmer; Giovanni Sotgiu; Giorgia Sulis; Carlos A Torres-Duque; Kazunori Umeki; Mukund Uplekar; Catharina van Weezenbeek; Tuula Vasankari; Robert J Vitillo; Constantia Voniatis; Maryse Wanlin; Mario C Raviglione
Journal:  Eur Respir J       Date:  2015-04       Impact factor: 16.671

8.  Management of Latent Tuberculosis Infection Among Healthcare Workers: 10-Year Experience at a Single Center.

Authors:  Esther Arguello Perez; Susan K Seo; William J Schneider; Cynthia Eisenstein; Arthur E Brown
Journal:  Clin Infect Dis       Date:  2017-11-29       Impact factor: 9.079

9.  What patient factors predict physicians' decision not to treat latent tuberculosis infection in tuberculosis contacts?

Authors:  Claudia C Dobler; Queenie Luu; Guy B Marks
Journal:  PLoS One       Date:  2013-09-30       Impact factor: 3.240

10.  A Step toward Tuberculosis Elimination in a Low-Incidence Country: Successful Diagnosis and Treatment of Latent Tuberculosis Infection in a Refugee Clinic.

Authors:  Elissa Rennert-May; Elisabeth Hansen; Toktam Zadeh; Valerie Krinke; Stan Houston; Ryan Cooper
Journal:  Can Respir J       Date:  2016-02-24       Impact factor: 2.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.